New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A

Roche Holdings AG  (OTC: RHHBY ) announced results from the primary analysis  of the phase 3 HAVEN 6 study of Hemlibra (emicizumab) in people with moderate or mild hemophilia A. The data showed that Hemlibra demonstrated a favorable safety profile and effective bleed control in patients ... Full story available on Benzinga.com